Recently, the administration of FXR agonists, the previously studied OCA, and the novel TC-100 (INT-787), markedly increased RECK mRNA expression and upregulated RECK protein in an HF diet-induced ob/ob mouse model of NASH [10] (Figure 2). Here, RECK is linked to metabolic dysfunction-associated steatohepatitis.